PL1686984T3 - Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych - Google Patents
Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowychInfo
- Publication number
- PL1686984T3 PL1686984T3 PL04819227T PL04819227T PL1686984T3 PL 1686984 T3 PL1686984 T3 PL 1686984T3 PL 04819227 T PL04819227 T PL 04819227T PL 04819227 T PL04819227 T PL 04819227T PL 1686984 T3 PL1686984 T3 PL 1686984T3
- Authority
- PL
- Poland
- Prior art keywords
- cyclohexyl
- dimethylaminomethyl
- phenol
- methoxyphenyl
- phenyl
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 3
- JIRYWFYYBBRJAN-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical compound CN(C)CC1CCCCC1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-UHFFFAOYSA-N 0.000 abstract 5
- 239000000935 antidepressant agent Substances 0.000 abstract 3
- 229940005513 antidepressants Drugs 0.000 abstract 3
- VTXTVLAQPBIPPF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=CC(C2C(CCCC2)CN(C)C)=C1 VTXTVLAQPBIPPF-UHFFFAOYSA-N 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- LOMMOGHGUYMOEF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC(C2C(CCCC2)C[N+](C)(C)[O-])=C1 LOMMOGHGUYMOEF-UHFFFAOYSA-N 0.000 abstract 1
- WMFQEDGHYPJQSG-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n-methylmethanamine Chemical compound CNCC1CCCCC1C1=CC=CC(OC)=C1 WMFQEDGHYPJQSG-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-(2-dimethylaminomethyl-cyclohexyl)-phenol N-oxide Chemical class 0.000 abstract 1
- WMRBLCTVXONZBT-UHFFFAOYSA-N 3-[2-(aminomethyl)cyclohexyl]phenol Chemical compound NCC1CCCCC1C1=CC=CC(O)=C1 WMRBLCTVXONZBT-UHFFFAOYSA-N 0.000 abstract 1
- KUGOVDMEUQXLRD-UHFFFAOYSA-N 3-[2-(methylaminomethyl)cyclohexyl]phenol Chemical compound CNCC1CCCCC1C1=CC=CC(O)=C1 KUGOVDMEUQXLRD-UHFFFAOYSA-N 0.000 abstract 1
- CKMPEIWYGQTXJB-UHFFFAOYSA-N 4-[2-[(dimethylamino)methyl]cyclohexyl]benzene-1,2-diol Chemical compound CN(C)CC1CCCCC1C1=CC=C(O)C(O)=C1 CKMPEIWYGQTXJB-UHFFFAOYSA-N 0.000 abstract 1
- FMGWPVLPVFJEAH-UHFFFAOYSA-N 6-[3-[2-[(dimethylamino)methyl]cyclohexyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OC2C(C(O)C(O)C(O2)C(O)=O)O)=C1 FMGWPVLPVFJEAH-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- NPZGGTZKFXTTSR-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]cyclohexyl]phenyl] hydrogen sulfate Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OS(O)(=O)=O)=C1 NPZGGTZKFXTTSR-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 239000003402 opiate agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000697 serotonin reuptake Effects 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10356362A DE10356362A1 (de) | 2003-11-28 | 2003-11-28 | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen |
| PCT/EP2004/013439 WO2005051375A1 (de) | 2003-11-28 | 2004-11-26 | Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen |
| EP04819227A EP1686984B1 (de) | 2003-11-28 | 2004-11-26 | Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1686984T3 true PL1686984T3 (pl) | 2011-10-31 |
Family
ID=34609453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08008351T PL1970060T3 (pl) | 2003-11-28 | 2004-11-26 | Zastosowanie związków C-(2-fenylocykloheksylo)-metylo-aminowych do terapii fibromyalgii |
| PL04819227T PL1686984T3 (pl) | 2003-11-28 | 2004-11-26 | Zastosowanie związków C-(2-fenylocykloheksylo)-metyloaminowych do terapii zaburzeń lękowych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08008351T PL1970060T3 (pl) | 2003-11-28 | 2004-11-26 | Zastosowanie związków C-(2-fenylocykloheksylo)-metylo-aminowych do terapii fibromyalgii |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060258741A1 (pl) |
| EP (2) | EP1970060B9 (pl) |
| JP (1) | JP5013875B2 (pl) |
| AT (1) | ATE509626T1 (pl) |
| CA (1) | CA2546672C (pl) |
| CY (2) | CY1113348T1 (pl) |
| DE (1) | DE10356362A1 (pl) |
| DK (2) | DK1686984T3 (pl) |
| ES (2) | ES2362752T3 (pl) |
| HR (1) | HRP20110608T1 (pl) |
| PL (2) | PL1970060T3 (pl) |
| PT (2) | PT1686984E (pl) |
| SI (2) | SI1686984T1 (pl) |
| WO (1) | WO2005051375A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050182131A1 (en) * | 2002-07-19 | 2005-08-18 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence |
| DE102005034973A1 (de) * | 2005-07-22 | 2007-02-15 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| DE102005034974A1 (de) * | 2005-07-22 | 2007-04-19 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| DE102005061428A1 (de) * | 2005-12-22 | 2007-08-16 | Grünenthal GmbH | Substituierte Cyclohexylmethyl-Derivate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19525137C2 (de) * | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
| US6387956B1 (en) * | 1999-03-24 | 2002-05-14 | University Of Cincinnati | Methods of treating obsessive-compulsive spectrum disorders |
| DE10059411A1 (de) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz |
| DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| DE10146275A1 (de) * | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| AU2002364517A1 (en) * | 2001-11-30 | 2003-06-17 | Sepracor Inc. | Tramadol analogs and uses thereof |
| DE10233048A1 (de) * | 2002-07-19 | 2004-01-29 | Grünenthal GmbH | Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken |
| DE10254785A1 (de) * | 2002-11-22 | 2004-06-03 | Grünenthal GmbH | Kombination ausgewählter Analgetika mit COX II-Inhibitoren |
| SI3241550T1 (sl) * | 2002-11-22 | 2020-11-30 | Grunenthal Gmbh | Uporaba (1R, 2R) -3- (3-dimetilimanino-1-etil-2-metil-propil)-fenola za zdravljenje vnetnih bolečin |
| DE102005011517A1 (de) * | 2005-03-10 | 2006-09-21 | Grünenthal GmbH | Transdermales therapeutisches System zur Verabreichung von Analgetika |
| US20090104266A1 (en) * | 2005-09-15 | 2009-04-23 | Tobias Jung | 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
-
2003
- 2003-11-28 DE DE10356362A patent/DE10356362A1/de not_active Ceased
-
2004
- 2004-11-26 EP EP08008351A patent/EP1970060B9/de not_active Expired - Lifetime
- 2004-11-26 PL PL08008351T patent/PL1970060T3/pl unknown
- 2004-11-26 HR HR20110608T patent/HRP20110608T1/hr unknown
- 2004-11-26 PT PT04819227T patent/PT1686984E/pt unknown
- 2004-11-26 EP EP04819227A patent/EP1686984B1/de not_active Expired - Lifetime
- 2004-11-26 CA CA2546672A patent/CA2546672C/en not_active Expired - Fee Related
- 2004-11-26 ES ES04819227T patent/ES2362752T3/es not_active Expired - Lifetime
- 2004-11-26 AT AT04819227T patent/ATE509626T1/de active
- 2004-11-26 DK DK04819227.2T patent/DK1686984T3/da active
- 2004-11-26 JP JP2006540395A patent/JP5013875B2/ja not_active Expired - Fee Related
- 2004-11-26 ES ES08008351T patent/ES2390931T3/es not_active Expired - Lifetime
- 2004-11-26 PL PL04819227T patent/PL1686984T3/pl unknown
- 2004-11-26 PT PT08008351T patent/PT1970060E/pt unknown
- 2004-11-26 SI SI200431677T patent/SI1686984T1/sl unknown
- 2004-11-26 DK DK08008351.2T patent/DK1970060T3/da active
- 2004-11-26 SI SI200431926T patent/SI1970060T1/sl unknown
- 2004-11-26 WO PCT/EP2004/013439 patent/WO2005051375A1/de not_active Ceased
-
2006
- 2006-05-25 US US11/440,005 patent/US20060258741A1/en not_active Abandoned
-
2009
- 2009-09-14 US US12/558,896 patent/US8084497B2/en not_active Expired - Fee Related
-
2010
- 2010-06-09 US US12/797,408 patent/US20100249225A1/en not_active Abandoned
-
2011
- 2011-06-21 CY CY20111100588T patent/CY1113348T1/el unknown
-
2012
- 2012-09-28 CY CY20121100904T patent/CY1113162T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1970060T3 (da) | 2012-10-01 |
| CY1113162T1 (el) | 2016-04-13 |
| SI1970060T1 (sl) | 2012-10-30 |
| DK1686984T3 (da) | 2011-06-20 |
| US20100004341A1 (en) | 2010-01-07 |
| US20060258741A1 (en) | 2006-11-16 |
| PT1970060E (pt) | 2012-10-02 |
| EP1686984B1 (de) | 2011-05-18 |
| CA2546672C (en) | 2013-01-22 |
| EP1970060B9 (de) | 2013-01-09 |
| WO2005051375A1 (de) | 2005-06-09 |
| PT1686984E (pt) | 2011-05-30 |
| EP1970060B1 (de) | 2012-08-29 |
| US8084497B2 (en) | 2011-12-27 |
| ES2390931T3 (es) | 2012-11-19 |
| CY1113348T1 (el) | 2016-06-22 |
| ES2362752T3 (es) | 2011-07-12 |
| EP1970060A3 (de) | 2009-04-15 |
| EP1970060A2 (de) | 2008-09-17 |
| HRP20110608T1 (hr) | 2011-10-31 |
| CA2546672A1 (en) | 2005-06-09 |
| DE10356362A1 (de) | 2005-06-23 |
| PL1970060T3 (pl) | 2012-11-30 |
| ATE509626T1 (de) | 2011-06-15 |
| US20100249225A1 (en) | 2010-09-30 |
| SI1686984T1 (sl) | 2011-07-29 |
| JP2007512288A (ja) | 2007-05-17 |
| EP1686984A1 (de) | 2006-08-09 |
| JP5013875B2 (ja) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6001884A (en) | Calcium receptor-active molecules | |
| CA2173747C (en) | Calcium receptor-active arylalkyl amines | |
| SI2010531T1 (sl) | Spirociklični cikloheksanski derivati z analgetskim učinkom | |
| CY1113162T1 (el) | Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων | |
| AU4195796A (en) | Calcium receptor-active compounds | |
| MXPA06012505A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central. | |
| AU2010236404A2 (en) | Monoamine reuptake inhibitors | |
| RU2007139543A (ru) | Производные бензодиоксана и бензодиоксолана и их применение | |
| US20090318451A1 (en) | Morpholine dopamine agonists for the treatment of pain | |
| RS50538B (sr) | Sulfonamidni derivati namenjeni lečenju bolesti | |
| MX2007011498A (es) | Derivados de n-(n-sulfonilaminometil)ciclopropanocarboxamida utiles para el tratamiento de dolor. | |
| JP2012144545A (ja) | アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ | |
| BG106912A (en) | Diphenyl ether compounds useful in therapy | |
| RU2006107534A (ru) | Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| JP2006522030A5 (pl) | ||
| JP2007513945A (ja) | 体熱感、衝動調節障害および一般的な病状による人格変化の治療 | |
| EP4161900A1 (en) | Cannabidiolic acid (cbda) derivatives and uses thereof | |
| JP2012524098A (ja) | ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物 | |
| JP5714580B2 (ja) | ３−フェノキシメチルピロリジン化合物 | |
| CA2492876A1 (en) | 1-phenyl-2-dimethylaminomethylcyclohexane compounds for therapy of depressive symptoms, pain, and incontinence | |
| JP7343641B2 (ja) | 神経伝達物質放出剤としてのビニローグフェネチルアミン | |
| JP2008532992A (ja) | ベンゾキサゾシンおよびそれらの治療的使用 | |
| HK1070351A (en) | Calcium receptor-active arylalkyl amines |